Press Releases

505(b)(2) NDA on track for FDA submission in Q1 2018

SOLANA BEACH, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the Oppenheimer & Co.

Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018

SOLANA BEACH, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global

Collaborated with Spaulding Clinical Research LLC and today announced the initiation of the comparative exposure pharmacokinetic (PK) study Partnered with Rho, Inc. for the preparation of the 505(b)(2) New Drug Application (NDA) for Gimoti™ NDA submission remains on track for late 2017/early

Expected to be final clinical trial prior to 505(b)(2) NDA submission

SOLANA BEACH, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Monday,

Company on track for late 2017/early 2018 submission

Confirmed FDA acceptability of comparative exposure pharmacokinetic (PK) study design and agreement on related CMC data package elements for Gimoti™ new drug application (NDA) Partnered with Spaulding Clinical Research to complete PK study in second half of 2017 Received FDA agreement that a

Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis